Juha W. Koskenvuo

Prof. Dr. Juha W. Koskenvuo

Blueprint Genetics, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Heart
Verified
Journal Article
Open access
PDF file
GHGeorg Hansmann
Georg Hansmann
Christian ApitzChristian Apitz
Christian Apitz
HAHashim Abdul-khaliq
Hashim Abdul-khaliq
TATero-Pekka Alastalo
Tero-Pekka Alastalo
PBPhillip Beerbaum
Phillip Beerbaum
PZPeter Zartner
Peter Zartner
The European Paediatric Pulmonary Vascular Disease (PVD) Network is a registered, non-profit organisation that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of paediatric pulmonary hypertensive vascular disease, including specific forms such as pulmonary arterial hypertension (PAH)-congenital heart disease, pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, persistent PH of the newborn, and related cardiac dysfunction. Methods The writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990–2015) and held five face-to-face meetings with votings. Clinical trials, guidelines, and reviews limited to paediatric data were searched using the terms ‘pulmonary hypertensioń’ and 5–10 other keywords, as outlined in the other nine articles of this special issue. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on paediatric data only, or on adult studies that included >10% children. Results A total of 9 original consensus articles with graded recommendations (COR/LOE) were developed, and are summarised here. The topics included diagnosis/monitoring, genetics/biomarker, cardiac catheterisation, echocardiography, cardiac magnetic resonance/chest CT, associated forms of PH, intensive care unit/ventricular assist device/lung transplantation, and treatment of paediatric PAH. Conclusions The multipaper expert consensus statement of the European Paediatric PVD Network provides a specific, comprehensive, detailed but practical framework for the optimal clinical care of children with PH.

7 February 2010 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
JKJuha W. Koskenvuo
Juha W. Koskenvuo
RMRachel Mirsky
Rachel Mirsky
YZYan Zhang
Yan Zhang
FAFranca S. Angeli
Franca S. Angeli
SJSarah Jahn
Sarah Jahn
YYYerem Yeghiazarians
Yerem Yeghiazarians
Pulmonary arterial hypertension (PAH) is a life-threatening condition characterized by progressive elevation in pulmonary artery pressure (PAP) and total pulmonary vascular resistance (TPVR). Recent advances in imaging techniques have allowed the development of new echocardiographic parameters to evaluate disease progression. However, there are no reports comparing the diagnostic performance of these non-invasive parameters to each other and to invasive measurements. Therefore, we investigated the diagnostic yield of echocardiographically derived TPVR and Doppler parameters of PAP in screening and measuring the severity of PAH in a rat model. Serial echocardiographic and invasive measurements were performed at baseline, 21 and 35 days after monocrotaline-induction of PAH. The most challenging echocardiographic derived TPVR measurement had good correlation with the invasive measurement (r = 0.92, P < 0.001) but also more simple and novel parameters of TPVR were found to be useful although the non-invasive TPVR measurement was feasible in only 29% of the studies due to lack of sufficient tricuspid valve regurgitation. However, echocardiographic measures of PAP, pulmonary artery flow acceleration time (PAAT) and deceleration (PAD), were measurable in all animals, and correlated with invasive PAP (r = −0.74 and r = 0.75, P < 0.001 for both). Right ventricular thickness and area correlated with invasive PAP (r = 0.59 and r = 0.64, P < 0.001 for both). Observer variability of the invasive and non-invasive parameters was low except in tissue-Doppler derived isovolumetric relaxation time. These non-invasive parameters may be used to replace invasive measurements in detecting successful disease induction and to complement invasive data in the evaluation of PAH severity in a rat model.

11 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OAOyediran Akinrinade
Oyediran Akinrinade
THTiina Heliö
Tiina Heliö
RDRonald H. Lekanne Deprez
Ronald H. Lekanne Deprez
JJJan D. H. Jongbloed
Jan D. H. Jongbloed
LBLudolf G. Boven
Ludolf G. Boven
JKJuha W. Koskenvuo
Juha W. Koskenvuo
Recent advancements in next generation sequencing (NGS) technology have led to the identification of the giant sarcomere gene, titin (TTN), as a major human disease gene. Truncating variants of TTN (TTNtv) especially in the A-band region account for 20% of dilated cardiomyopathy (DCM) cases. Much attention has been focused on assessment and interpretation of TTNtv in human disease; however, missense and non-frameshifting insertions/deletions (NFS-INDELs) are difficult to assess and interpret in clinical diagnostic workflow. Targeted sequencing covering all exons of TTN was performed on a cohort of 530 primary DCM patients from three cardiogenetic centres across Europe. Using stringent bioinformatic filtering, twenty-nine and two rare TTN missense and NFS-INDELs variants predicted deleterious were identified in 6.98% and 0.38% of DCM patients, respectively. However, when compared with those identified in the largest available reference population database, no significant enrichment of such variants was identified in DCM patients. Moreover, DCM patients and reference individuals had comparable frequencies of splice-region missense variants with predicted splicing alteration. DCM patients and reference populations had comparable frequencies of rare predicted deleterious TTN missense variants including splice-region missense variants suggesting that these variants are not independently causative for DCM. Hence, these variants should be classified as likely benign in the clinical diagnostic workflow, although a modifier effect cannot be excluded at this stage.

1 March 2001 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
JKJuha W. Koskenvuo
Juha W. Koskenvuo
HSHajime Sakuma
Hajime Sakuma
PNPekka Niemi
Pekka Niemi
JTJyri O. Toikka
Jyri O. Toikka
JKJuhani Knuuti
Juhani Knuuti
JHJaakko J. Hartiala
Jaakko J. Hartiala
Coronary flow reserve (CFR) measurements have been widely used in assessing the functional significance of coronary artery stenosis because they are more sensitive in predicting major cardiac events than angiographically detected reductions of coronary arteries. Myocardial blood flow can be determined by measuring coronary sinus (CS) flow with velocity‐encoded cine magnetic resonance imaging (VEC‐MRI). The purpose of this study was to compare global myocardial blood flow (MBF) and CFR measured using VEC‐MRI with MBF and CFR measured using positron emission tomography (PET). We measured MBF at baseline and after dipyridamole‐induced hyperemia in 12 male volunteers with VEC‐MRI and PET. With VEC‐MRI, MBF was 0.64 ± 0.09 (ml/min/g) at baseline and 1.59 ± 0.79 (ml/min/g) at hyperemia, which yielded an average CFR of 2.51 ± 1.29. With PET, MBF was 0.65 ± 0.20 (ml/min/g) at baseline and 1.78 ± 0.72 (ml/min/g) at hyperemia, which yielded an average CFR of 2.79 ± 0.97. The correlation of MBFs between these two methods was good (r = 0.82, P < 0.001). The CFRs measured by MRI correlated well with those measured using PET (r = 0.76, P < 0.004). These results suggest that MRI is a useful and accurate method to measure global MBF and CFR. Therefore, it would be suitable for studying risk factor modifications of vascular function at an early stage in healthy volunteers. J. Magn. Reson. Imaging 2001;13:361–366.

23 May 2008 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JKJuha W. Koskenvuo
Juha W. Koskenvuo
JHJ. J. Hartiala
J. J. Hartiala
PNP. Nuutila
P. Nuutila
RKR. Kalliokoski
R. Kalliokoski
JVJ. S. Viikari
J. S. Viikari
IKI. M. Kantola
I. M. Kantola

3 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJuha W. Koskenvuo
Juha W. Koskenvuo
ISInka Saarinen
Inka Saarinen
SASaija Ahonen
Saija Ahonen
JTJohanna Tommiska
Johanna Tommiska
SWSini Weckström
Sini Weckström
THTiina Heliö
Tiina Heliö
Background: Familial dilated cardiomyopathy (DCM) is typically a monogenic disorder with dominant inheritance. Although over 40 genes have been linked to DCM, more than half of the patients undergoing comprehensive genetic testing are left without molecular diagnosis. Recently, biallelic protein-truncating variants (PTVs) in the nebulin-related anchoring protein gene (NRAP) were identified in a few patients with sporadic DCM. Methods and results: We determined the frequency of rare NRAP variants in a cohort of DCM patients and control patients to further evaluate role of this gene in cardiomyopathies. A retrospective analysis of our internal variant database consisting of 31,639 individuals who underwent genetic testing (either panel or direct exome sequencing) was performed. The DCM group included 577 patients with either a confirmed or suspected DCM diagnosis. A control cohort of 31,062 individuals, including 25,912 individuals with non-cardiac (control group) and 5,150 with non-DCM cardiac indications (Non-DCM cardiac group). Biallelic (n = 6) or two (n = 5) NRAP variants (two PTVs or PTV+missense) were identified in 11 unrelated probands with DCM (1.9%) but none of the controls. None of the 11 probands had an alternative molecular diagnosis. Family member testing supports co-segregation. Biallelic or potentially biallelic NRAP variants were enriched in DCM vs. controls (OR 1052, p<0.0001). Based on the frequency of NRAP PTVs in the gnomAD reference population, and predicting full penetrance, biallelic NRAP variants could explain 0.25%-2.46% of all DCM cases. Conclusion: Loss-of-function in NRAP is a cause for autosomal recessive dilated cardiomyopathy, supporting its inclusion in comprehensive genetic testing.